Testosterone supplementation and prostate cancer, controversies still exist.
Late onset hypogonadism is a common condition in aging males. The population of men who can be potentially treated with testosterone supplementation is growing. Controversy that surrounds testosterone replacement therapy is due to generally undefined lower limits of normal testosterone level and high prevalence of hypogonadal symptoms in elderly population and the non-specific nature of these symptoms. Incidence of prostate hyperplasia and occult prostate cancer in elderly are both high. The risk that testosterone treatment would trigger prostate cancer was not fully recognized. The aim of this mini review is to present a risk of carcinogenesis within the prostate related to testosterone treatment.
Drewa
Tomasz
T
Department of Urology, N. Copernicus University, Bydgoszcz, Karłowicza 24, 85-092 Bydgoszcz, Poland. tomaszdrewa@wp.pl
Chłosta
Piotr
P
D016922:Cellular Senescence; D019587:Dietary Supplements; D006801:Humans; D008297:Male; D011467:Prostate / Q000187:drug effects; D011471:Prostatic Neoplasms / Q000139:chemically induced*; D013739:Testosterone / Q000009:adverse effects*
D013739:Testosterone